Geode Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-64,092
| Closed | -$161K | – | 4223 |
|
|
2020
Q2 | $161K | Buy |
64,092
+22,353
| +54% | +$42.4K | ﹤0.01% | 3719 |
|
|
2020
Q1 | $53K | Buy |
41,739
+10,913
| +35% | +$22.3K | ﹤0.01% | 3914 |
|
|
2019
Q4 | $86K | Buy |
30,826
+10,541
| +52% | +$33.8K | ﹤0.01% | 3998 |
|
|
2019
Q3 | $107K | Sell |
20,285
-1,238
| -6% | -$8.25K | ﹤0.01% | 3934 |
|
|
2019
Q2 | $206K | Sell |
21,523
-7,261
| -25% | -$134K | ﹤0.01% | 3781 |
|
|
2019
Q1 | $771K | Buy |
28,784
+1,192
| +4% | +$30.3K | ﹤0.01% | 3269 |
|
|
2018
Q4 | $623K | Buy |
27,592
+1,093
| +4% | +$42.7K | ﹤0.01% | 3286 |
|
|
2018
Q3 | $1.46M | Buy |
26,499
+1,054
| +4% | +$67.3K | ﹤0.01% | 3053 |
|
|
2018
Q2 | $1.82M | Buy |
25,445
+3,759
| +17% | +$265K | ﹤0.01% | 2909 |
|
|
2018
Q1 | $1.33M | Buy |
21,686
+298
| +1% | +$26.2K | ﹤0.01% | 2986 |
|
|
2017
Q4 | $2.69M | Buy |
21,388
+325
| +2% | +$41.6K | ﹤0.01% | 2591 |
|
|
2017
Q3 | $2.88M | Buy |
21,063
+4,979
| +31% | +$666K | ﹤0.01% | 2537 |
|
|
2017
Q2 | $2.29M | Buy |
16,084
+414
| +3% | +$64K | ﹤0.01% | 2651 |
|
|
2017
Q1 | $2.88M | Buy |
15,670
+2,278
| +17% | +$255K | ﹤0.01% | 2443 |
|
|
2016
Q4 | $1.08M | Buy |
13,392
+360
| +3% | +$28.5K | ﹤0.01% | 2949 |
|
|
2016
Q3 | $998K | Buy |
13,032
+200
| +2% | +$16K | ﹤0.01% | 2935 |
|
|
2016
Q2 | $1.1M | Buy |
12,832
+1,169
| +10% | +$107K | ﹤0.01% | 2850 |
|
|
2016
Q1 | $1.08K | Buy |
11,663
+86
| +0.7% | +$8.59K | ﹤0.01% | 2839 |
|
|
2015
Q4 | $2.32M | Buy |
11,577
+235
| +2% | +$46.9K | ﹤0.01% | 2377 |
|
|
2015
Q3 | $1.69M | Sell |
11,342
-1
| -0% | -$734 | ﹤0.01% | 2551 |
|
|
2015
Q2 | $10.8M | Buy |
11,343
+860
| +8% | +$703K | 0.01% | 1363 |
|
|
2015
Q1 | $7.68M | Buy |
10,483
+1,832
| +21% | +$1.38M | ﹤0.01% | 1573 |
|
|
2014
Q4 | $6.87M | Buy |
8,651
+4,174
| +93% | +$2.25M | ﹤0.01% | 1618 |
|
|
2014
Q3 | $1.79M | Buy |
4,477
+143
| +3% | +$38.3K | ﹤0.01% | 2426 |
|
|
2014
Q2 | $1.17M | Buy |
4,334
+225
| +5% | +$48.3K | ﹤0.01% | 2707 |
|
|
2014
Q1 | $894K | Buy |
4,109
+438
| +12% | +$122K | ﹤0.01% | 2855 |
|
|
2013
Q4 | $992K | Buy |
3,671
+1,274
| +53% | +$304K | ﹤0.01% | 2718 |
|
|
2013
Q3 | $546K | Buy |
2,397
+327
| +16% | +$57.1K | ﹤0.01% | 2904 |
|
|
2013
Q2 | $291K | Buy |
+2,070
| New | +$328K | ﹤0.01% | 3097 |
|
Geode Capital Management's TTPH Position: Q3 2020 in Review
Geode Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q3 2020, closing a stake of 64,092 shares — an estimated $161K sold.
Geode Capital Management first reported a position in TTPH in Q2 2013 and held it in 29 quarters. The position peaked at $10.8M in Q2 2015. 1 fund tracked by Wall St. Rank holds TTPH as of Q3 2020.
- Geode Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
- Geode Capital Management sold 64,092 Tetraphase Pharmaceuticals, Inc. shares in Q3 2020, an estimated $161K.
- Geode Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
- Geode Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $10.8M in Q2 2015.
- 1 fund tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q3 2020.
Based on Geode Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.